{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:39:27Z","timestamp":1794609567185,"version":"4.9.1"},"reference-count":120,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.vaccine.2023.08.047","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T22:16:11Z","timestamp":1694470571000},"page":"6194-6205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer"],"prefix":"10.1016","volume":"41","author":[{"given":"Miriam","family":"Reuschenbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Doorbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"del Pino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmar A.","family":"Joura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosybel","family":"Drury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rauscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred J.","family":"Saah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2023.08.047_b0005","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.047_b0010","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/14760584.2017.1383158","article-title":"9-Valent human papillomavirus vaccine: a review of the clinical development program","volume":"16","author":"Luxembourg","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2023.08.047_b0015","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2023.08.047_b0020","doi-asserted-by":"crossref","unstructured":"de Sanjos\u00e9 S, Serrano B, Tous S, Alejo M, Lloveras B, Quir\u00f3s B, et al. Burden of human papillomavirus (HPV)-related cancers attributable to HPVs 6\/11\/16\/18\/31\/33\/45\/52 and 58. JNCI Cancer Spectrum 2019;2:pky045.","DOI":"10.1093\/jncics\/pky045"},{"key":"10.1016\/j.vaccine.2023.08.047_b0025","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/597071","article-title":"Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine","volume":"199","author":"Garland","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.047_b0030","unstructured":"World Health Organization (WHO). Human papillomavirus vaccines: WHO position paper. Wkly Epidemiol Rec 2017;92:241-68."},{"key":"10.1016\/j.vaccine.2023.08.047_b0035","doi-asserted-by":"crossref","first-page":"698","DOI":"10.15585\/mmwr.mm6832a3","article-title":"Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices","volume":"68","author":"Meites","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.08.047_b0040","unstructured":"European Medicines Agency (EMA). Gardasil 9 Summary of Product Characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/gardasil-9-epar-product-information_en.pdf; 2020 [accessed September 9, 2020]."},{"key":"10.1016\/j.vaccine.2023.08.047_b0045","unstructured":"Merck Sharp & Dohme LLC, Rahway, NJ, USA. Gardasil\u00ae9 US Prescribing Information, https:\/\/www.merck.com\/product\/usa\/pi_circulars\/g\/gardasil_9\/gardasil_9_pi.pdf; 2023 [accessed 17 April 2023]."},{"key":"10.1016\/j.vaccine.2023.08.047_b0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.annonc.2019.11.004","article-title":"Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature","volume":"31","author":"Kalliala","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0055","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1186\/s12885-020-07452-6","article-title":"Risk of HPV-related extra-cervical cancers in women treated for cervical intraepithelial neoplasia","volume":"20","author":"Preti","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.vaccine.2023.08.047_b0060","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1200\/JCO.2016.71.4543","article-title":"Long-lasting increased risk of human papillomavirus-related carcinomas and premalignancies after cervical intraepithelial neoplasia grade 3: a population-based cohort study","volume":"35","author":"Ebisch","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0065","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/ijc.32752","article-title":"Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status","volume":"147","author":"Sand","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2023.08.047_b0070","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S1470-2045(17)30700-3","article-title":"Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis","volume":"18","author":"Arbyn","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0075","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ygyno.2020.08.025","article-title":"Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser conization: a 5-year follow-up study","volume":"159","author":"Bogani","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0080","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4161\/hv.5.10.9515","article-title":"Evaluation of quadrivalent HPV 6\/11\/16\/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection","volume":"5","author":"Olsson","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2023.08.047_b0085","doi-asserted-by":"crossref","first-page":"16086","DOI":"10.1038\/nrdp.2016.86","article-title":"Carcinogenic Human Papillomavirus Infection","volume":"2","author":"Schiffman","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.vaccine.2023.08.047_b0090","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/infdis\/jiaa557","article-title":"Rates of new human papillomavirus detection and loss of detection in middle-aged women by recent and past sexual behavior","volume":"223","author":"Paul","year":"2021","journal-title":"J Infect Dis"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2023.08.047_b0095","doi-asserted-by":"crossref","first-page":"F24","DOI":"10.1016\/j.vaccine.2012.05.089","article-title":"Updating the natural history of human papillomavirus and anogenital cancers","volume":"30","author":"Moscicki","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.047_b0100","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/infdis\/jit018","article-title":"Concordance and transmission of human papillomavirus within heterosexual couples observed over short intervals","volume":"207","author":"Widdice","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.047_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2023.199068","article-title":"Elimination of reserve cells for prevention of HPV-associated cervical cancer","volume":"329","author":"Reich","year":"2023","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2023.08.047_b0110","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.coviro.2021.09.014","article-title":"Principles of epithelial homeostasis control during persistent human papillomavirus infection and its deregulation at the cervical transformation zone","volume":"51","author":"Doorbar","year":"2021","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0115","first-page":"771","article-title":"Cytokeratin 17 and p63 are markers of the HPV target cell, the cervical stem cell","volume":"24","author":"Martens","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.vaccine.2023.08.047_b0120","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1158\/1055-9965.283.14.1","article-title":"Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women","volume":"14","author":"Viscidi","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.vaccine.2023.08.047_b0125","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1128\/CMR.05028-11","article-title":"Epithelial cell responses to infection with human papillomavirus","volume":"25","author":"Stanley","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2023.08.047_b0130","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2174\/1874357901206010241","article-title":"The immune response to papillomavirus during infection persistence and regression","volume":"6","author":"Hibma","year":"2012","journal-title":"Open Virol J"},{"key":"10.1016\/j.vaccine.2023.08.047_b0135","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/OLQ.0b013e3181ad25ff","article-title":"Prevalence and incidence of HPV genital infection in women","volume":"36","author":"Velicer","year":"2009","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2023.08.047_b0140","doi-asserted-by":"crossref","first-page":"e53067","DOI":"10.1371\/journal.pone.0053067","article-title":"HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays","volume":"8","author":"Lin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.08.047_b0145","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/jnci\/djq384","article-title":"Epidemiological study of anti-HPV16\/18 seropositivity and subsequent risk of HPV16 and -18 infections","volume":"102","author":"Safaeian","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2023.08.047_b0150","article-title":"Naturally acquired HPV antibodies against subsequent homotypic infection: A large-scale prospective cohort study","volume":"13","author":"Yao","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.vaccine.2023.08.047_b0155","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pvr.2015.06.007","article-title":"Seroconversion following anal and genital HPV infection in men: the HIM study","volume":"1","author":"Giuliano","year":"2015","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.vaccine.2023.08.047_b0160","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1158\/0008-5472.CAN-11-0751","article-title":"Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men","volume":"72","author":"Lu","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2023.08.047_b0165","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0140-6736(10)62342-2","article-title":"Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study","volume":"377","author":"Giuliano","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.08.047_b0170","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1086\/604729","article-title":"Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003\u20132004","volume":"200","author":"Markowitz","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.047_b0175","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1002\/ijc.30391","article-title":"Prior human papillomavirus-16\/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: post-hoc analysis from a randomized controlled trial","volume":"139","author":"Garland","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2023.08.047_b0180","doi-asserted-by":"crossref","first-page":"e1401","DOI":"10.1136\/bmj.e1401","article-title":"Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data","volume":"344","author":"Joura","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2023.08.047_b0185","unstructured":"Joura E, Kjaer SK, Bautista O, Luxembourg A, Saah A, Giuliano AR. Effect of the 9-valent human papillomavirus (9vHPV) vaccine in a subgroup of female clinical trial participants who underwent cervical surgery. EUROGIN 2022 International Multidisciplinary HPV Congress 2022;abstract MSS 02-5."},{"key":"10.1016\/j.vaccine.2023.08.047_b0190","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s12889-020-8371-z","article-title":"Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN?","volume":"20","author":"Karimi-Zarchi","year":"2020","journal-title":"A randomized trial BMC Public Health"},{"key":"10.1016\/j.vaccine.2023.08.047_b0195","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00404-018-4926-y","article-title":"Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease","volume":"298","author":"Pieralli","year":"2018","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.vaccine.2023.08.047_b0200","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1093\/cid\/ciaa1456","article-title":"Human papillomavirus vaccination prior to loop electroexcision procedure does not prevent recurrent cervical high-grade squamous intraepithelial lesions in women living with human immunodeficiency virus: a randomized, double-blind, placebo-controlled trial","volume":"73","author":"Firnhaber","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.047_b0205","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/vaccines8020245","article-title":"HPV vaccination as adjuvant to conization in women with cervical intraepithelial neoplasia: a study under real-life conditions","volume":"8","author":"Del Pino","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.08.047_b0210","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2018.08.033","article-title":"SPERANZA project: HPV vaccination after treatment for CIN2","volume":"151","author":"Ghelardi","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0215","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3390\/vaccines8040717","article-title":"Assessing the long-term role of vaccination against hpv after loop electrosurgical excision procedure (leep): a propensity-score matched comparison","volume":"8","author":"Bogani","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.08.047_b0220","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/vaccines8010045","article-title":"Efficacy of HPV vaccination in women receiving LEEP for cervical dysplasia: a single institution's experience","volume":"8","author":"Petrillo","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.08.047_b0225","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2013.04.050","article-title":"Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2\u20133)?","volume":"130","author":"Kang","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0230","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/vaccines10020288","article-title":"Effectiveness of prophylactic human papillomavirus vaccine in the prevention of recurrence in women conized for HSIL\/CIN 2\u20133: the VENUS study","volume":"10","author":"Casajuana-P\u00e9rez","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.08.047_b0235","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/vaccines9050410","article-title":"Adjuvant HPV Vaccination to prevent recurrent cervical dysplasia after surgical treatment: a meta-analysis","volume":"9","author":"Di Donato","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.08.047_b0240","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ijgc-2020-001197","article-title":"Prophylactic human papillomavirus vaccination to prevent recurrence of cervical intraepithelial neoplasia: a meta-analysis","volume":"30","author":"Bartels","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.vaccine.2023.08.047_b0245","doi-asserted-by":"crossref","first-page":"6402","DOI":"10.1016\/j.vaccine.2020.07.055","article-title":"Prophylactic HPV vaccination after conization: A systematic review and meta-analysis","volume":"38","author":"Jentschke","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.047_b0250","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/AOG.0000000000003833","article-title":"Adjuvant human papillomavirus vaccine to reduce recurrent cervical dysplasia in unvaccinated women: a systematic review and meta-analysis","volume":"135","author":"Lichter","year":"2020","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0255","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejogrb.2021.11.008","article-title":"If prophylactic HPV vaccination is considered in a woman with CIN2+, what is the value and should it be given before or after the surgical treatment?","volume":"269","author":"Tjalma","year":"2022","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0260","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/aogs.14359","article-title":"Human papillomavirus vaccination in women undergoing excisional treatment for cervical intraepithelial neoplasia and subsequent risk of recurrence: A systematic review and meta-analysis","volume":"101","author":"Eriksen","year":"2022","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.vaccine.2023.08.047_b0265","doi-asserted-by":"crossref","first-page":"e070135","DOI":"10.1136\/bmj-2022-070135","article-title":"Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis","volume":"378","author":"Kechagias","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2023.08.047_b0270","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.3390\/vaccines10091543","article-title":"Human papillomavirus vaccine impact and effectiveness in six high-risk populations: a systematic literature review","volume":"10","author":"Goodman","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.08.047_b0275","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3390\/vaccines10060887","article-title":"HPV vaccination in women with cervical intraepithelial neoplasia undergoing excisional treatment: insights into unsolved questions","volume":"10","author":"Henere","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.08.047_b0280","unstructured":"ClinicalTrials.gov. Nonavalent prophylactic HPV vaccine (GARDASIL9) after local conservative the NOVEL trial (NOVEL), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03979014; [accessed February 16]."},{"key":"10.1016\/j.vaccine.2023.08.047_b0285","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1186\/s12885-020-07025-7","article-title":"Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial","volume":"20","author":"van de Laar","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.vaccine.2023.08.047_b0290","unstructured":"ClinicalTrials.gov. Impact on disease relapse of HPV vaccination in women treated with LEEP for cervical intraepithelial neoplasia. HOPE9, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03848039; [accessed February 16]."},{"key":"10.1016\/j.vaccine.2023.08.047_b0295","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/vaccines9020083","article-title":"Surgical treatment of vulvar HSIL: adjuvant HPV vaccine reduces recurrent disease","volume":"9","author":"Ghelardi","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.08.047_b0300","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/cid\/cir1036","article-title":"Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study","volume":"54","author":"Swedish","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.047_b0305","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1097\/QAD.0000000000002928","article-title":"HPV vaccination to prevent recurrence of anal intraepithelial neoplasia in HIV+ MSM","volume":"35","author":"Gosens","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2023.08.047_b0310","doi-asserted-by":"crossref","first-page":"e93393","DOI":"10.1371\/journal.pone.0093393","article-title":"Prevention of anal condyloma with quadrivalent human papillomavirus vaccination of older men who have sex with men","volume":"9","author":"Swedish","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.08.047_b0315","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.1016\/j.vaccine.2015.09.071","article-title":"Impact of quadrivalent human papillomavirus vaccine in women at increased risk of genital warts burden: Population-based cross-sectional survey of Czech women aged 16 to 40 years","volume":"33","author":"Petr\u00e1\u0161","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.047_b0320","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1111\/jsm.12670","article-title":"Impact of the quadrivalent HPV vaccine on disease recurrence in men exposed to HPV Infection: a randomized study","volume":"11","author":"Coskuner","year":"2014","journal-title":"J Sex Med"},{"key":"10.1016\/j.vaccine.2023.08.047_b0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta24470","article-title":"Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT","volume":"24","author":"Gilson","year":"2020","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.vaccine.2023.08.047_b0330","first-page":"1135","volume":"271","author":"Chiril\u0103","year":"2014","journal-title":"Head Neck Surg"},{"key":"10.1016\/j.vaccine.2023.08.047_b0335","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/lio2.80","article-title":"Recurrent respiratory papillomatosis (RRP)-time for a reckoning?","volume":"2","author":"Kin Cho Goon","year":"2017","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0340","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijporl.2016.01.032","article-title":"Effectiveness of the human papillomavirus (types 6, 11, 16, and 18) vaccine in the treatment of children with recurrent respiratory papillomatosis","volume":"83","author":"Hermann","year":"2016","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0345","first-page":"3255","volume":"271","author":"Ho\u010devar-Bolte\u017ear","year":"2014","journal-title":"Head Neck Surg"},{"key":"10.1016\/j.vaccine.2023.08.047_b0350","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/lary.27993","article-title":"Multi-year effect of human papillomavirus vaccination on recurrent respiratory papillomatosis","volume":"130","author":"Matsuzaki","year":"2020","journal-title":"Laryngoscope"},{"key":"10.1016\/j.vaccine.2023.08.047_b0355","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12879-018-3260-0","article-title":"HPV vaccination as preventive approach for recurrent respiratory papillomatosis - a 22-year retrospective clinical analysis","volume":"18","author":"Mauz","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.047_b0360","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/coa.13076","article-title":"A retrospective case-control analysis of the efficacy of Gardasil","volume":"43","author":"Milner","year":"2018","journal-title":"Clin Otolaryngol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0365","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00106-017-0378-0","article-title":"Treatment outcomes of recurrent respiratory papillomatosis : Retrospective analysis of juvenile and adult cases","volume":"66","author":"Papaioannou","year":"2018","journal-title":"HNO"},{"key":"10.1016\/j.vaccine.2023.08.047_b0370","first-page":"3231","article-title":"Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis","volume":"273","author":"Tjon Pian Gi","year":"2016","journal-title":"Eur Arch Oto-Rhino-Laryngol : Off J Eur Federation Oto-Rhino-Laryngological Societies (EUFOS): Affiliated German Soc Oto-Rhino-Laryngol - Head Neck Surg"},{"key":"10.1016\/j.vaccine.2023.08.047_b0375","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/0003489418821695","article-title":"Implementation of routine HPV vaccination in the management of recurrent respiratory papillomatosis","volume":"128","author":"Yiu","year":"2019","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0380","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jvoice.2014.08.003","article-title":"The use of the quadrivalent human papillomavirus vaccine (gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma","volume":"29","author":"Young","year":"2015","journal-title":"J Voice"},{"key":"10.1016\/j.vaccine.2023.08.047_b0385","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/infdis\/jiy616","article-title":"Therapeutic use of the human papillomavirus vaccine on recurrent respiratory papillomatosis: a systematic review and meta-analysis","volume":"219","author":"Rosenberg","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.047_b0390","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jamaoto.2022.1190","article-title":"Outcomes after human papillomavirus vaccination in patients with recurrent respiratory papillomatosis: a nonrandomized clinical trial","volume":"148","author":"Smahelova","year":"2022","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.vaccine.2023.08.047_b0395","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/ijc.25940","article-title":"Impact of an HPV6\/11\/16\/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16\/18 infection","volume":"129","author":"Haupt","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2023.08.047_b0400","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/v9100267","article-title":"Natural history of HPV infection across the lifespan: role of viral latency","volume":"9","author":"Gravitt","year":"2017","journal-title":"Viruses"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2023.08.047_b0405","doi-asserted-by":"crossref","first-page":"F55","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"The biology and life-cycle of human papillomaviruses","volume":"30","author":"Doorbar","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.047_b0410","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bpobgyn.2017.08.001","article-title":"Host control of human papillomavirus infection and disease","volume":"47","author":"Doorbar","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0415","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.coviro.2013.06.003","article-title":"Latent papillomavirus infections and their regulation","volume":"3","author":"Doorbar","year":"2013","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvr.2023.200268","article-title":"The human Papillomavirus twilight zone - Latency, immune control and subclinical infection","volume":"16","author":"Doorbar","year":"2023","journal-title":"Tumour Virus Res"},{"key":"10.1016\/j.vaccine.2023.08.047_b0425","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.pvr.2019.02.004","article-title":"Whole tissue cervical mapping of HPV infection: Molecular evidence for focal latent HPV infection in humans","volume":"7","author":"Hammer","year":"2019","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.vaccine.2023.08.047_b0430","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/cid\/ciab985","article-title":"Proportion of incident genital human papillomavirus detections not attributable to transmission and potentially attributable to latent infections: implications for cervical cancer screening","volume":"75","author":"Malag\u00f3n","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.047_b0435","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/aogs.14362","article-title":"Evidence of latent HPV infection in older Danish women with a previous history of cervical dysplasia","volume":"101","author":"Hammer","year":"2022","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.vaccine.2023.08.047_b0440","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/modpathol.2015.52","article-title":"Stratification of HPV-induced cervical pathology using the virally encoded molecular marker E4 in combination with p16 or MCM","volume":"28","author":"Griffin","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0445","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nrc.2018.13","article-title":"Opportunities and challenges for human papillomavirus vaccination in cancer","volume":"18","author":"Roden","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.vaccine.2023.08.047_b0450","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.virol.2013.05.038","article-title":"The papillomavirus major capsid protein L1","volume":"445","author":"Buck","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2023.08.047_b0455","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ygyno.2010.04.004","article-title":"Current understanding of the mechanism of HPV infection","volume":"118","author":"Schiller","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0460","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ygyno.2019.03.253","article-title":"Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population","volume":"154","author":"Giuliano","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0465","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24\u201345 years of age","volume":"105","author":"Castellsagu\u00e9","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2023.08.047_b0470","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/jmv.20800","article-title":"High-risk HPV presence in cervical specimens after a large loop excision of the cervical transformation zone: significance of newly detected hr-HPV genotypes","volume":"79","author":"van Ham","year":"2007","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0475","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijid.2019.09.006","article-title":"HPV vaccination: Are we overlooking additional opportunities to control HPV infection and transmission?","volume":"88","author":"Vorsters","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.047_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103177","article-title":"Dynamics of papillomavirus in vivo disease formation & susceptibility to high-level disinfection-Implications for transmission in clinical settings","volume":"63","author":"Egawa","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2023.08.047_b0485","doi-asserted-by":"crossref","first-page":"e13606","DOI":"10.1097\/MD.0000000000013606","article-title":"Persistent HPV-16 infection leads to recurrence of high-grade cervical intraepithelial neoplasia","volume":"97","author":"Byun","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.vaccine.2023.08.047_b0490","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ebiom.2016.06.042","article-title":"A single human papillomavirus vaccine dose improves b cell memory in previously infected subjects","volume":"10","author":"Scherer","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2023.08.047_b0495","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.3390\/v7072802","article-title":"Human papillomaviruses; epithelial tropisms, and the development of neoplasia","volume":"7","author":"Egawa","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2023.08.047_b0500","doi-asserted-by":"crossref","first-page":"JVI0118121","DOI":"10.1128\/jvi.01181-21","article-title":"Role of E6 in maintaining the basal cell reservoir during productive papillomavirus infection","author":"Saunders-Wood","year":"2022","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0505","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fimmu.2020.00188","article-title":"The use of both therapeutic and prophylactic vaccines in the therapy of papillomavirus disease","volume":"11","author":"Garbuglia","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0510","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fmicb.2019.03116","article-title":"Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy","volume":"10","author":"Pal","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0515","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.19.02444","article-title":"Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer","volume":"38","author":"Chera","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0520","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1089\/hum.2017.197","article-title":"Therapeutic DNA vaccines for human papillomavirus and associated diseases","volume":"29","author":"Cheng","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2023.08.047_b0525","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jdcr.2020.02.002","article-title":"Systemic and intratumoral 9-valent human papillomavirus vaccine treatment for squamous cell carcinoma in situ in a renal transplant recipient","volume":"6","author":"Nichols","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.vaccine.2023.08.047_b0530","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0535","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1590\/s1677-5538.ibju.2018.0355","article-title":"Can quadrivalent human papillomavirus prophylactic vaccine be an effective alternative for the therapeutic management of genital warts? an exploratory study","volume":"45","author":"Choi","year":"2019","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.vaccine.2023.08.047_b0540","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.7.1700857","article-title":"Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016","volume":"24","author":"Mart\u00ednez-G\u00f3mez","year":"2019","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2023.08.047_b0545","first-page":"8510","article-title":"Extending Human Papillomavirus (HPV) vaccination beyond female adolescents and after treatment for high grade CIN: the Italian HPV Study Group (IHSG) review and position paper","volume":"24","author":"Origoni","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.vaccine.2023.08.047_b0550","unstructured":"SEGO O. Prevenci\u00f3n del c\u00e1ncer de cuello de \u00fatero. Gu\u00edas de pr\u00e1ctica cl\u00ednica en c\u00e1ncer ginecol\u00f3gico y mamario., https:\/\/www.mscbs.gob.es\/fr\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/calendario-y-coberturas\/docs\/CalendarioVacunacion_GRadultos.pdf; 2014 [accessed 5 October 2021]."},{"key":"10.1016\/j.vaccine.2023.08.047_b0555","unstructured":"Salud CIdSNd. Calendario recomendado a\u00f1o 2021, http:\/\/www.aepcc.org\/wp-content\/uploads\/2016\/01\/AEPCC_revista02.pdf; 2021 [accessed 5 October 2021]."},{"key":"10.1016\/j.vaccine.2023.08.047_b0560","unstructured":"Manitoba Health. Manatoba's immunization program: vaccines offered free-of-charge, https:\/\/www.gov.mb.ca\/health\/publichealth\/cdc\/vaccineeligibility.html; 2021 [accessed June 5, 2022]."},{"key":"10.1016\/j.vaccine.2023.08.047_b0565","unstructured":"Prince Edward Island Department of Health and Wellness. Human papillomavirus (HPV) vaccine (Gardasil\u00ae 9), https:\/\/www.princeedwardisland.ca\/en\/information\/health-and-wellness\/human-papillomavirus-hpv-vaccine-gardasilr-9; 2018 [accessed June 5, 2022]."},{"key":"10.1016\/j.vaccine.2023.08.047_b0570","unstructured":"European Medicines Agency (EMA). Gardasil Summary of Product Characteristics, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000703\/WC500021142.pdf; 2019 [accessed November 11, 2019]."},{"key":"10.1016\/j.vaccine.2023.08.047_b0575","doi-asserted-by":"crossref","first-page":"e190819","DOI":"10.1001\/jamanetworkopen.2019.0819","article-title":"Effect of human papillomavirus vaccine to interrupt recurrence of vulvar and anal neoplasia (VIVA): a trial protocol","volume":"2","author":"Stankiewicz Karita","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2023.08.047_b0580","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1016\/j.vaccine.2017.08.006","article-title":"Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: The time is now","volume":"35","author":"Deshmukh","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.047_b0585","first-page":"239","article-title":"Therapeutic use of human papillomavirus vaccines in cervical lesions","volume":"72","author":"Castro-Eguiluz","year":"2020","journal-title":"Rev Invest Clin"},{"key":"10.1016\/j.vaccine.2023.08.047_b0590","first-page":"656","article-title":"Could the human papillomavirus recombinant vaccine be a new valid approach in the management of ano-genital warts?","volume":"34","author":"Sarro","year":"2022","journal-title":"Ann Ig"},{"key":"10.1016\/j.vaccine.2023.08.047_b0595","doi-asserted-by":"crossref","first-page":"e49974","DOI":"10.1371\/journal.pone.0049974","article-title":"E4 antibodies facilitate detection and type-assignment of active HPV infection in cervical disease","volume":"7","author":"Griffin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.08.047_b0600","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.virol.2013.07.008","article-title":"The E4 protein; structure, function and patterns of expression","volume":"445","author":"Doorbar","year":"2013","journal-title":"Virology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23009908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23009908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:32:36Z","timestamp":1759404756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23009908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":120,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0264410X23009908"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.08.047","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.08.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}